The transcription factor family activator protein 2 (TFAP2) is vital for regulating both
embryonic and oncogenic development. The TFAP2 family consists of five DNA-binding …

Breast cancer remains one of the leading causes of cancer-related deaths globally and the
most prominent among females, yet with limited effective therapeutic options. Most of the …

Endocrine therapy is the frontline treatment for estrogen receptor (ER) positive breast cancer
patients. However, the primary and acquired resistance to endocrine therapy drugs remain …

The epithelial to mesenchymal transition (EMT) has been proposed to contribute to the
metastatic spread of breast cancer cells. EMT-promoting transcription factors determine a …

Astrocyte-microglial interaction plays a crucial role in brain injury-associated
neuroinflammation. Our previous data illustrated that astrocytes secrete microRNA, leading …

Hematological and neurological expressed 1 like (HN1L) is a newly identified oncogene in
lung cancer and hepatocellular carcinoma recently identified by our team, but its roles in the …

The vascular endothelial growth factor receptor (VEGFR) network contributes to breast
cancer pathogenesis and progression. Anlotinib is a highly potent multi‑target tyrosine …

Tumor-associated carbonic anhydrases IX (CAIX) and XII (CAXII) have long been in the
spotlight as potential new targets for anti-cancer therapy. Recently, CAIX/CAXII specific …

Abstract Activator Protein 2 gamma (AP-2γ) is a master transcription factor that plays a
critical role in the development and progression of breast cancer. However, the underlying …

A significant proportion of estrogen receptor‐positive (ER+) breast cancer (BC) initially
responds to endocrine therapy but eventually evolves into therapy‐resistant BC …